Studies on immunoproteasome in human liver. Part I: Absence in fetuses, presence in normal subjects, and increased levels in chronic active hepatitis and cirrhosis

Biochemical and Biophysical Research Communications

Volumn 397, Issue 2, 2010, Pages 301-306

  Vasuri, Francesco ^a   Capizzi, Elisa ^a   Bellavista, Elena ^b   Mishto, Michele ^b,c   Santoro, Aurelia ^b   Fiorentino, Michelangelo ^a   Capri, Miriam ^b   Cescon, Matteo ^a   Grazi, Gian Luca ^a   Grigioni, Walter Franco ^a   D'Errico Grigioni, Antonia ^a   Franceschi, Claudio ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chronic active hepatitis; Cirrhosis; Fetal liver; Immunohistochemistry; Immunoproteasome; Inflammation

Indexed keywords

IMMUNOPROTEASOME; LOW MOLECULAR MASS POLYPEPTIDE 2; LOW MOLECULAR MASS POLYPEPTIDE 7; POLYPEPTIDE; PROTEASOME; PROTEASOME ACTIVATOR 28 ALPHA BETA; REGULATOR PROTEIN; UNCLASSIFIED DRUG; CYSTEINE PROTEINASE; LMP 2 PROTEIN; LMP-2 PROTEIN; LMP7 PROTEIN; MULTIENZYME COMPLEX; MUSCLE PROTEIN; PSME1 PROTEIN, HUMAN; PSME2 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN; CHRONIC ACTIVE HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENZYME LOCALIZATION; FEMALE; FETUS; FETUS LIVER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; LIVER CELL; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; WESTERN BLOTTING; CHRONIC DISEASE; ENZYMOLOGY; HEPATITIS; LIVER; METABOLISM; MIDDLE AGED; PRENATAL DEVELOPMENT;

PROTEA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; CYSTEINE ENDOPEPTIDASES; FEMALE; FETUS; HEPATITIS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIENZYME COMPLEXES; MUSCLE PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; YOUNG ADULT;

EID: 77955501824     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.05.104     Document Type: Article

References (23)

1. K.L. Rock, C. Gramm, L. Rothstein, et al., Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules, Cell 78 (1994) 761-771.
2. K. Tanaka, The proteasome: overview of structure and functions, Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 85 (2009) 12-36.
3. P.M. Kloetzel, Antigen processing by the proteasome, Nat. Rev. Mol. Cell Biol. 2 (2001) 179-187.
4. K. Tanaka, M. Kasahara, The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28, Immunol. Rev. 163 (1998) 161-176.
5. C. Noda, N. Tanahashi, N. Shimbara, et al., Tissue distribution of constitutive proteasomes, immunoproteasomes, and PA28 in rats, Biochem. Biophys. Res. Commun. 277 (2000) 348-354.
6. N. Klare, M. Seeger, K. Janek, et al., Intermediate-type 20 S proteasomes in HeLa cells: "asymmetric" subunit composition, diversity and adaptation, J. Mol. Biol. 373 (2007) 1-10.
7. A. Visekruna, N. Slavova, S. Dullat, et al., Expression of catalytic proteasome subunits in the gut of patients with Crohn's disease, Int. J. Colorectal Dis. 24 (2009) 1133-1139.
8. A. Visekruna, T. Joeris, N. Schmidt, et al., Comparative expression analysis and characterization of 20S proteasomes in human intestinal tissues: the proteasome pattern as diagnostic tool for IBD patients, Inflamm. Bowel Dis. 15 (2009) 526-533.
9. M. Mishto, E. Bellavista, A. Santoro, et al., Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains, Neurobiol. Aging 27 (2006) 54-66.
10. M. Mishto, E. Bellavista, C. Ligorio, et al., Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population, Plos One 5 (2010) e9287.
11. M. Díaz-Hernández, F. Hernández, E. Martín-Aparicio, et al., Neuronal induction of the immunoproteasome in Huntington's disease, J. Neurosci. 23 (2003) 11653-11661.
12. K. Puttaparthi, J.L. Elliott, Non-neuronal induction of immunoproteasome subunits in an ALS model: possible mediation by cytokines, Exp. Neurol. 196 (2005) 441-451.
13. R. Marfella, C. Di Filippo, M.T. Laieta, et al., Effects of ubiquitin-proteasome system deregulation on the vascular senescence and atherosclerosis process in elderly patients, J. Gerontol. A Biol. Sci. Med. Sci. 63 (2008) 200-203.
14. N.A. Osna, T.M. Donohue, Implication of altered proteasome function in alcoholic liver injury, World J. Gastroenterol. 13 (2007) 4931-4937.
15. M.P. Bousquet-Dubouch, S. Nguen, D. Bouyssié, et al., Chronic ethanol feeding affects proteasome-interacting proteins, Proteomics 9 (2009) 3609-3622.
16. J. Oliva, J. Dedes, J. Li, et al., Epigenetics of proteasome inhibition in the liver of rats fed ethanol chronically, World J. Gastroenterol. 15 (2009) 705-712.
17. M.D. Robek, M.L. Garcia, B.S. Boyd, et al., Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus, J. Virol. 81 (2007) 483-491.
18. S. Khan, M. van den Broek, K. Schwarz, et al., Immunoproteasomes largely replace constitutive proteasomes during antiviral and antibacterial immune response in the liver, J. Immunol. 167 (2001) 6859-6868.
19. M. Fiorentino, A. D'Errico, B. Corti, et al., A multiorgan donor cancer screening protocol: the Italian Emilia-Romagna region experience, Transplantation 76 (2003) 1695-1699.
20. K. Ishak, A. Baptista, L. Bianchi, et al., Histological grading and staging of chronic hepatitis, J. Hepatol. 22 (1995) 696-699.
21. E. Bellavista, M. Mishto, A. Santoro, et al., Immunoproteasome in Macaca fascicularis: no age-dependent modification of abundance and activity in the brain and insight into an in silico structural model, Rejuvenation Res. 11 (2008) 73-82.
22. E.L. Potter, Pathology of the Fetus, Infant and Child, second ed., Mosby, Elsevier, 2007.
23. E. Biagi, L. Nylund, M. Candela, et al., Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians, PlosOne 5 (2010) e10667.